英文药名：BRILINTA Tablets(Ticagrelor)

中文药名：替卡格雷片

生产厂家：阿斯利康制药

ブリリンタ錠60mg／ブリリンタ錠90mg

治疗类别名称
抗血小板剂
批准日期：2017年2月
欧文商標名
BRILINTA Tablets 60mg
BRILINTA Tablets 90mg
一般名：チカグレロル（Ticagrelor）（JAN）
化学名：(1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
構造式：

分子式：C23H28F2N6O4S
分子量：522.57
性　状：
这是淡红色粉白色。
条件批准
在建立药品风险管理，要正确用药。
适应病症
抗血栓药物，用于减少急性冠脉综合征（ACS）患者的心血管死亡和心脏病发作。
用法与用量
急性冠脉综合征（不稳定型心绞痛，非ST段抬高心肌梗死，ST段抬高心肌梗死）
成人，180毫克，每日二次，每次90毫克。
心肌梗死
成人，每日一次，每次60毫克。
包装规格
片剂
60毫克：[PTP]140片（14片×10）[瓶装]250片
90毫克：[PTP]140片（14片×10）[瓶装]250片
制造厂商
阿斯利康有限公司
注：使用以原处方资料为准：http://www.info.pmda.go.jp/go/pack/3399011F1027_1_03/
Acquired domestic manufacturing and marketing approval for AstraZeneca antiplatelet drug "BRYLITA ® tablets 60 mg / 90 mg"
AstraZeneca Co., Ltd. (head office: Osaka prefecture Osaka-shi, President: David Fredriksson, hereinafter AstraZeneca) is an acute coronary syndrome (ACS) of the antiplatelet drug "BRILLINTA® tablet 60 mg / 90 mg" (generic name: Tikagurol) ) And Chen old myocardial infarction (OMI), we have announced the approval of manufacturing and marketing in Japan.
This drug is an oral antiplatelet drug that exerts its effect by directly and reversibly inhibiting the platelet ADP receptor (P2Y12). Since it does not require activation of metabolism in the liver for the onset of action, the platelet aggregation inhibitory action from early stage is obtained and the action quickly disappears after administration is completed. Furthermore, it is a drug that is not affected by genetic polymorphisms of metabolic enzymes, and has little effect on individual differences among patients.
product name
Buririnta ® tablets 60 mg/90mg
common name
Chikagurol
Indication
Briilla tablet 90 mg: Acute coronary syndrome to which percutaneous transluminal coronary angioplasty (PCI) is applied (unstable angina, non-ST elevation myocardial infarction, ST elevation myocardial infarction) (However, two antiplatelet agents including aspirin Only when the therapy is appropriate and it is difficult to administer other antiplatelet agents to be used in combination with aspirin)
Buririnta tablet 60 mg: Chen old myocardial infarction having one or more of the following risk factors, the risk of developing atherothrombosis is particularly high
Diabetes requiring medication therapy, a history of two or more myocardial infarctions, coronary artery disease with multiple branch lesions confirmed by angiography, or end-stage chronic renal dysfunction
Dosage regimen
Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction, ST elevation myocardial infarction)
Usually, adults are orally administered twice daily with an initial dose of 180 mg as chikogreol and a maintenance dose of 90 mg after the second dose.
Old old myocardial infarction
Usually, adults are orally administered 60 mg once a day as tikagreol.
Manufacture and market approval
September 28, 2016
Manufacturer selling agency
AstraZeneca Corporation
With this approval acquisition, we will contribute to the improvement of the quality of life (QOL) of the medical staff in Japan and the patient's daily life by providing new options for the treatment of ischemic heart disease
About Buririnta ® tablets
BRYLINTA ® tablets are oral antiplatelet agents used in the treatment of ACS and OMI, which are classified as cyclopentyl-triazolo-pyrimidines (CPTPs) and directly act on P2Y12 receptors. BRYLINTA ® tablets have been approved for ACS indications in over 120 countries including the West and the USA, and have been approved in past medicine for myocardial infarction in the US and Europe. It is recommended in 12 major world ACS guidelines and contributes to the treatment of more than 2.2 million patients. Buririnta ® is a registered trademark of the AstraZeneca group.